FACULTY
A Pharmacist's Guide to Anticonvulsants
Paper Symposium
Activity Date: July 2005  — Activity Info: Volume 2, (2)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired) | Order Copy of Activity

 

Full Disclosure Policy Affecting CE Activities:
As a sponsor accredited by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:

PROGRAM DIRECTOR

Stephanie J. Phelps, PharmD
Professor
Pharmacy and Pediatrics
University of Tennessee College of Pharmacy
Memphis, Tennessee
Dr Phelps reports serving as a consultant to Eisai Inc, and holding stock in Elan Corporation and Pfizer Inc.

PARTICIPATING FACULTY

Jeannine M. Conway, PharmD
Assistant Professor
Experimental and Clinical Pharmacology
University of Minnesota College of Pharmacy
Minneapolis, Minnesota
Dr Conway reports having no significant financial or advisory relationships with corporate organizations related to this activity.

William R. Garnett, PharmD
Professor of Pharmacy and Neurology
Virginia Commonwealth University
Medical College of Virginia
Richmond, Virginia
Dr Garnett reports receiving grants/research support from Altec, Eisai Inc, GlaxoSmithKline, and Philip Morris USA; serving as a consultant to EdSource, King Pharmaceuticals, Inc, MedPointe Pharmaceuticals, and Meridian Laboratory; serving on the speakers’ bureau for Abbott Laboratories, Bimark Medical Communications, CD Ford, Eisai Inc, Shire Pharmaceuticals Group plc, and UCB Pharma; and holding stock in Amgen Inc, Merck & Co, Inc, and Pfizer Inc.

Barry E. Gidal, PharmD, RPh
Professor of Pharmacy and Neurology
University of Wisconsin School of Pharmacy
Madison, Wisconsin
Dr Gidal reports receiving grants/research support from GlaxoSmithKline and UCB Pharma; servings as a consultant to GlaxoSmithKline, UCB Pharma, and XenoPort, Inc; and receiving honoraria from GlaxoSmithKline, Novartis Pharmaceuticals USA, and UCB Pharma.

Kevan VanLandingham, MD, PhD
Associate Clinical Professor
Department of Neurology
Duke University Medical Center
Durham, North Carolina
Dr VanLandingham reports serving as a consultant to Eisai Inc, GlaxoSmithKline, UCB Pharma, and Valeant Pharmaceuticals.

Notice: In accordance with the ACPE Criteria for Quality, the audience is advised that articles in this continuing pharmaceutical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.

Dr Gidal—clonazepam, diazepam, carbamazepine, gabapentin, phenytoin, primidone, topiramate, valproate.

All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

     
Home | Contact Us | View Account | Need Help?